TITLE

Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies

AUTHOR(S)
Burn, D. J.; Rowan, E. N.; Allan, I. M.; Molloy, S.; O'Brien, J. I.; McKeith, I. G.
PUB. DATE
May 2006
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;May2006, Vol. 77 Issue 5, p585
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: A previous cross sectional study found over-representation of a postural instability gait difficulty (PIGD) motor subtype in Parkinson's disease patients with dementia (PDD) and dementia with Lewy bodies (DLB), compared with Parkinson's disease (PD). Aims: (1) To examine rates of cognitive and motor decline over two years in PD (n = 40), PDD (n = 42) and DLB (n = 41) subjects, compared with age matched controls (n = 41), (2) to record whether motor phenotypes of PD, PDD, and DLB subjects changed during the study, (3) to find out if cognitive and motor decline in PD was associated with baseline motor subtype, and (4) to report the incidence of dementia in PD patients in relation to baseline motor subtype. Results: Most of PDD and DLB participants were PIGD subtype at baseline assessment. In the non-demented PD group, tremor dominant (ID) and PIGD subtypes were more evenly represented. Cognitive decline over two years was greater in PDD and DLB groups (mean decline in MMSE -4.5 and -3.9, respectively), compared with PD (-0.2) and controls (-0.3). There was an association between PIGD subtype and increased rate of cognitive decline within the PD group. Of 40 PD patients, 25% of the 16 PIGD subtype developed dementia over two years, compared with none of the 18 TD or six indeterminate phenotype cases (χ² = 6.7, Fisher's exact test p < 0.05). Conclusion: A PIGD motor subtype is associated with a faster rate of cognitive decline in PD and may be considered a risk factor for incident dementia in PD.
ACCESSION #
20788354

 

Related Articles

  • Diagnosing dementia with Lewy bodies. Walker, Z.; Walker, R.W.H. // Current Medical Literature: Parkinson's Disease;2003, Vol. 5 Issue 1, p1 

    Provides information on dementia with Lewy bodies. Clinical diagnostic criteria; Pattern of cognitive deficit; Parkinsonian features.

  • Dementia with Lewy Bodies: Clinical Features and Treatment. Campbell, S.; Stephens, S.; Ballard, C. // Drugs & Aging;2001, Vol. 18 Issue 6, p397 

    Dementia with Lewy bodies (DLB) accounts for 15 to 20% of late-onset dementias. The overlap of cognitive symptoms, neuropsychiatric features, parkinsonism and severe sensitivity to antipsychotic drugs raise a number of key management issues. The neurochemical profile of DLB provides a good...

  • Abundant neuritic inclusions and microvacuolar changes in a case of diffuse Lewy body disease with the A53T mutation in the α-synuclein gene. Yamaguchi, Keiji; Cochran, Elizabeth J.; Murrell, Jill R.; Polymeropoulos, Mihael H.; Shannon, Kathleen M.; Crowther, R. Anthony; Goedert, Michel; Ghetti, Bernardino // Acta Neuropathologica;Sep2005, Vol. 110 Issue 3, p298 

    We report here a case of diffuse Lewy body disease with the A53T mutation in the α-synuclein gene. The proband presented at the age of 41 years with parkinsonism that was poorly responsive to levodopa. She subsequently developed cognitive impairment and moderate dementia, and died at the age...

  • Intellectual, mnemonic, and frontal functions in dementia with Lewy bodies: A comparison with early and advanced Parkinson's disease. Downes, John Joseph; Priestley, Nicholas M.; Doran, Mark; Ferran, Jose; Ghadiali, Eric; Cooper, Paul // Behavioural Neurology;1998, Vol. 11 Issue 3, p173 

    Both Parkinson's disease (PD) and dementia with Lewy bodies (DLB) share a common neuropathological marker, the presence of Lewy bodies in brain stem and basal forebrain nuclei. DLB, in addition, is associated with Lewy bodies in the neocortex, and, in it's more common form, with Alzheimer-type...

  • Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. Molloy, S. A.; Rowan, E. N.; O'Brien, J. T.; McKeith, I. G.; Wesnes, K.; Burn, D. J. // Journal of Neurology, Neurosurgery & Psychiatry;Dec2006, Vol. 77 Issue 12, p1323 

    Background: Levodopa (L-dopa) is the gold standard treatment for Parkinson's disease, but a lack of clear efficacy combined with a perceived liability to neuropsychiatric side effects has limited L-dopa use in patients with parkinsonism and dementia. Therefore, the effect of L-dopa on the...

  • Recent Knowledge on Molecular Components of Lewy Bodies Discloses Future Therapeutic Strategies in Parkinson's Disease. F. Fornai; P. Lenzi; M. Gesi; M. Ferrucci; G. Lazzeri; G. Natale; S. Ruggieri; A. Paparelli // Current Drug Targets - CNS & Neurological Disorders;Jun2003, Vol. 2 Issue 3, p149 

    Lewy bodies (LB) were first described by Lewy in 1912 [1] as neuronal pale eosinophilic inclusions which became a pathological hallmark of Parkinson's disease (PD). In his original study, Lewy defined these inclusions as pale eosinophilic cytoplasmic structures, and studies since then have...

  • Neurology and Psychiatry: Parkinson's Disease.  // Current Medical Literature: Health Care of Older People;2003, Vol. 16 Issue 2, p39 

    Analyzes whether Parkinson's disease with dementia and dementia with Lewy bodies (DLB) are two separate entities or the same condition at different positions along the spectrum of diseases associated with Lewy bodies. Autopsy of patients who had Lewy body disease; Clinical features of DLB;...

  • Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease. Mezey, E.; Dehejia, A.M.; Harta, G.; Suchy, S.F.; Nussbaum, R.L.; Brownstein, M.J.; Polymeropoulos, M.H. // Molecular Psychiatry;1998, Vol. 3 Issue 6, p493 

    A missense mutation in the human alpha synuclein gene was recently identified in some cases of familial Parkinson's disease (FPD). We have developed an antibody that recognizes the Cterminal 12 amino acids of the human alpha synuclein protein and have demonstrated that alpha synuclein is an...

  • Dual Task Interference During Gait in People With Parkinson Disease: Effects of Motor Versus Cognitive Secondary Tasks. O'Shea, Simone; Morris, Meg E; Iansek, Robert // Physical Therapy;Sep2002, Vol. 82 Issue 9, p888 

    Background and Purpose. Exacerbation of movement disorders while doing 2 tasks (dual task performance) is a characteristic feature of Parkinson disease (PD). The aim of this investigation was to identify whether the type of secondary task (motor or cognitive) determined the severity of dual task...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics